PROCEPT BioRobotics (NASDAQ:PRCT) Cut to “Underperform” at Bank of America

PROCEPT BioRobotics (NASDAQ:PRCT) was downgraded by Bank of America from a “neutral” rating to an “underperform” rating in a research note issued to investors on Thursday,Finviz reports. They presently have a $20.00 price objective on the stock. Bank of America‘s price target indicates a potential downside of 28.16% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. Wells Fargo & Company reaffirmed an “overweight” rating on shares of PROCEPT BioRobotics in a research report on Thursday. Morgan Stanley lowered their price target on PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. Leerink Partners restated an “outperform” rating and issued a $55.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Finally, UBS Group started coverage on PROCEPT BioRobotics in a report on Friday, December 12th. They set a “buy” rating and a $62.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics has an average rating of “Moderate Buy” and a consensus price target of $51.60.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT opened at $27.84 on Thursday. The business’s 50-day moving average price is $30.37 and its 200 day moving average price is $33.71. The company has a current ratio of 8.44, a quick ratio of 7.20 and a debt-to-equity ratio of 0.14. PROCEPT BioRobotics has a twelve month low of $26.23 and a twelve month high of $70.80. The company has a market capitalization of $1.56 billion, a PE ratio of -18.20 and a beta of 0.99.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The company had revenue of $76.38 million for the quarter, compared to analyst estimates of $93.70 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The company’s revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.35) EPS. On average, research analysts predict that PROCEPT BioRobotics will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several hedge funds have recently modified their holdings of the stock. Prosight Management LP raised its holdings in PROCEPT BioRobotics by 1,692.4% in the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock valued at $43,415,000 after acquiring an additional 1,303,009 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after purchasing an additional 1,262,928 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares during the last quarter. Chicago Capital LLC grew its stake in PROCEPT BioRobotics by 175.7% in the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock worth $55,992,000 after purchasing an additional 999,873 shares in the last quarter. Finally, Westfield Capital Management Co. LP increased its holdings in PROCEPT BioRobotics by 113.5% in the second quarter. Westfield Capital Management Co. LP now owns 1,598,349 shares of the company’s stock valued at $92,065,000 after buying an additional 849,792 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Management raised FY‑2026 revenue guidance to $390M–$410M, topping the Street estimate (~$384M) and suggesting confidence in the business trajectory for the year. PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
• Positive Sentiment: Revenue grew ~11.9% year‑over‑year in Q4, showing underlying top‑line momentum despite the quarter missing Street revenues. Listen to Conference Call / View Press Release
• Neutral Sentiment: Bullish research and feature pieces reiterate a longer‑term growth thesis for PROCEPT in urology robotics, which can support sentiment but don’t change near‑term fundamentals. PROCEPT BioRobotics Corporation (PRCT): A Bull Case Theory
• Negative Sentiment: Q4 results missed materially: EPS was ($0.53) vs. a consensus loss of ($0.32), and revenue was $76.38M vs. $93.7M expected — a sizable shortfall that pressured near‑term optics. PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Q1‑2026 revenue guidance of $79M–$82M is well below the consensus (~$93.7M), signaling a weak start to 2026 and creating short‑term downside risk; company did not provide EPS guidance. PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.